The phase 1b/2 study PANACEA enrolled patients with HER2-positive advanced breast cancer progressing after trastuzumab-based therapy in two subgroups (PD-L1-positive and PD-L1-negative) to receive pembrolizumab plus trastuzumab. This evidence concerns the gene CD274 and breast carcinoma.